Market cap
$19 Mln
Recently Viewed
Clear AllMarket cap
$19 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
0
Div. Yield
0 %
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
$0 Mln
ROE
0 %
ROCE
-- %
Industry P/E
--
EV/EBITDA
0
Debt to Equity
0
Book Value
$--
EPS
$--
Face value
--
Shares outstanding
8,131,081
CFO
$-188.83 Mln
EBITDA
$-160.19 Mln
Net Profit
$-229.26 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Rain Therapeutics (RAIN)
| -59.8 | -22.7 | -19.8 | -8.7 | -32.2 | -31.7 | -- |
|
BSE Sensex
| -9.5 | 5.5 | -6.0 | -4.3 | 8.7 | 9.9 | 11.5 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2023
|
2022
|
|---|---|---|
|
Rain Therapeutics (RAIN)
| -85.0 | -37.9 |
|
S&P Small-Cap 600
| 13.9 | -17.4 |
|
BSE Sensex
| 18.7 | 4.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Rain Therapeutics (RAIN)
|
2.4 | 18.6 | 0.0 | -12.1 | -- | -- | -- | 0.0 |
| 74.9 | 9,733.6 | 1,091.0 | 202.3 | 31.6 | 31.3 | 43.4 | 17.1 | |
| 65.4 | 8,216.2 | 88.0 | -785.0 | -808.1 | 197.5 | -- | 60.3 | |
| 45.3 | 11,658.3 | 2,320.1 | 782.6 | 39.0 | 35.5 | 16.1 | 5.3 | |
| 87.7 | 11,852.6 | 982.0 | -416.3 | -42.1 | 348.4 | -- | 55.7 | |
| 65.9 | 8,209.1 | 1,396.6 | 316.9 | 59.8 | 153.6 | 27.1 | 161.7 | |
| 515.1 | 12,204.5 | 958.4 | -288.3 | -27.8 | -42.5 | -- | 20.3 | |
| 403.4 | 14,867.3 | 2,530.2 | 451.1 | 21.3 | 70.2 | 34 | 32.4 | |
| 108.3 | 8,460.0 | 0.0 | -425.4 | -- | -36.7 | -- | 6.8 | |
| 333.7 | 9,538.9 | 0.0 | -303.3 | -- | -45.8 | -- | 10.9 |
Rain Enhancement Technologies Holdco, Inc. develops, manufactures, and commercializes ionization rainfall generation technology. It plans to develop improvements on existing rainfall generation technologies by introducing robust measurement tools,... including software monitoring technology, machine learning, rain gauges, and weather stations. The company was founded in 2022 and is headquartered in Naples, Florida. Read more
Co-Founder, CEO & Chairman
Mr. Avanish Vellanki M.B.A.
Co-Founder, CEO & Chairman
Mr. Avanish Vellanki M.B.A.
Headquarters
Naples, FL
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Rain Therapeutics Inc (RAIN) is $2.35 (NASDAQ) as of 24-Apr-2026 10:02 EDT. Rain Therapeutics Inc (RAIN) has given a return of -32.23% in the last 3 years.
Since, TTM earnings of Rain Therapeutics Inc (RAIN) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
--
|
--
|
|
2024
|
--
|
--
|
|
2023
|
-2.75
|
-1.88
|
|
2022
|
-0.42
|
-149.74
|
|
2021
|
11.74
|
0.37
|
The 52-week high and low of Rain Therapeutics Inc (RAIN) are Rs 8.50 and Rs 1.98 as of 24-Apr-2026.
Rain Therapeutics Inc (RAIN) has a market capitalisation of $ 19 Mln as on 17-Apr-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Rain Therapeutics Inc (RAIN), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.